Drugs / MK-1075
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02461563 | Jun → Dec 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02392494 | Apr → Aug 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02392494 ↗ |
| Route | Oral | “oral administration” NCT02392494 ↗ |